NeOnc Technologies Holdings, Inc. is trading at $4.84, down 8.2% as investors take profits following a significant regular-session rally on June 18, 2026.
- The company received Investigational New Drug (IND) approval from the Abu Dhabi Department of Health to advance its brain cancer drug, NEO212, into Phase 2 clinical trials in the UAE.
- The current downward move reflects a market reassessment and profit-taking after the initial surge triggered by the positive regulatory milestone.
- NEO212 is a lead candidate in the company's oncology pipeline, designed to provide a more effective treatment option for patients with brain cancer.